BriaCell Therapeutics 

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Earnings data Q2 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?

Why Is BriaCell (BCTX) Stock Moving Today?

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer. Bria-IMT is a cell-based immunotherapy.

Why BriaCell Therapeutics Stock Is Surging Today

PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer (breast cancer that has spread beyond the breast).

BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented the development details of its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, summarized in a poster session held at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.

BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

PHILADELPHIA and VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, is currently being manufactured at a cGMP facility and undergoing quality control testing for the potential upcoming clinical trial for patients with advanced breast cancer.

BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board.

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer (CMO), effective today.

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the “Meeting”) held virtually via teleconference on January 18, 2022 were passed. Voting for each of the director nominees was as follows:

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to announce that its common shares will commence trading on the Toronto Stock Exchange ("TSX") as of the opening of trading on Friday, December 31, 2021 (the "Effective Date"). The Company's common shares will continue to trade under its existing Canadian market symbol "BCT". The Company's common shares will concurrently be de-listed from the TSX Venture Exchange ("TSX-V") as of the Effective Date. The common shares and publicly-traded warrants remain trading on the Nasdaq Capital Market ("Nasdaq") under the symbols BCTX and BCTXW, respectively.

BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq

The shares of Briacell Therapeutics Corp (NASDAQ:BTCX) are up 6.8% at $8.53 this morning, following the company's announcement that an insider intends to acquire up to 1.59 million shares, which represents 10% of its public market securities.

Big Trade Sends Briacell Therapeutics Stock Higher

NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, presented clinical results from its lead clinical candidate Bria-IMT™ in a poster session held on December 8, 2021 during the 2021 San Antonio Breast Cancer Symposium® (SABCS) (the “Poster”).

BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®

NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitors, retifanlimab and epacadostat.

BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following updates:

BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

AerSale Corp

Big 5 Sporting Goods

Progenity

Cassava Sciences Inc

Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:GME) or AMC Entertainment Holdings Inc (NYSE:AMC). A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report

NEW YORK and VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.

BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favorite restaurant or dry cleaner, imagine the impact of losing a company that had devoted itself to enhancing the lives of women with breast cancer.

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the “Board”) has authorized the Company's repurchase program whereby the Company may purchase through the facilities of the TSX Venture Exchange ("TSXV") or The NASDAQ Capital Market ("NASDAQ") (i) up to 1,341,515 common shares (the “Common Shares”) and (ii) up to 411,962 publicly traded BCTXW warrants (the “Listed Warrants”) in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the "public float" as of September 8, 2021, over the next 12 months (the “Buyback”). Independent Trading Group (ITG) Inc. will act as the Company's advisor and dealer manager in respect of the Buyback. The Company expects to finalize the terms of the Buyback and formally commence the Buyback by September 14, 2021, subject to obtaining any necessary regulatory approvals.

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Mr. Marc Lustig to the Company's Board of Directors, effective September 1, 2021. Marc, through his investment company L5 Capital Inc., owns 1,530,000 common shares of BriaCell, representing 10.0% of BriaCell's issued and outstanding common shares.

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies. Under the agreement terms, ImaginAb will supply clinical doses of its CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in BriaCell's ongoing Phase 1/2a study with Incyte Corporation (NASDAQ: INCY) in metastatic or locally recurrent breast cancer patients.

BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial

BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization. In the U.S., 12.9% of women born in the country today will develop breast cancer at some time during their lifetime.

BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies

BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ: INCY).  The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's retifanlimab & epacadostat to treat advanced breast cancer.

BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment

NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.

News for BriaCell Therapeutics Stock (BCTX)